• Tetra Bio-Pharma Announces the Initiation of its Phase I Trial of PPP001 (dried Cannabis)

    23 February 2017
    0 Views

    Ottawa, Ontario – (Marketwired – February 23, 2017) – PhytoPain Pharma (PPP), a subsidiary of Tetra BioPharma Inc. (“Tetra” or the “Company”) (CSE:TBP) (OTCPINK:GRPOF), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain is pleased to announce the launch of its Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Multiple Daily Ascending Doses of Cannabis (Delta-9 tetrahydrocannabinol/ Cannabidiol) by Smoking/Inhalation in Healthy Male and Female Volunteers.

    Continue Reading
  • Tetra Bio-Pharma Reports Approval by Health Canada of its Phase I Trial of PPP001 (dried Cannabis)

    16 February 2017
    0 Views

    Ottawa, Ontario – (Marketwired – February 16, 2017) – PhytoPain Pharma Inc. (PPP), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP) (OTCPINK: GRPOF), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain is pleased to announce that the Therapeutic Products Directorate (TPD) of Health Canada has approved its Phase I clinical study of smoked cannabis.

    Continue Reading
  • Tetra Bio-Pharma and IntelGenx Announce the Signing of a Term Sheet for the Development and Commercialization of a Dronabinol XL Tablet

    9 February 2017
    0 Views

    Ottawa, Ontario – (February 9, 2017) – Tetra Bio-Pharma Inc. (“Tetra”) (CSE: TBP) (OTCPINK:GRPOF) and IntelGenx Corp. (“IntelGenx”), (TSXV: IGX) (OTCQX: IGXT), today announced the signing of a binding term sheet for the development and commercialization of a drug product containing dronabinol. Under the binding term sheet, Tetra will have exclusive rights to sell the product in North America with a right of first negotiation for outside the U.S. and Canada. The U.S. cancer pain market is expected to reach $5 billion in 2018.

    Continue Reading
  • Tetra Bio-Pharma Inc. Enters into Distribution and Supply Agreement with Engen Medical Corporation

    6 February 2017
    0 Views

    Ottawa, Ontario – (Marketwired – February 6, 2017) – Agro-Tek Inc. (“Agro-Tek”) a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP) (OTCPINK:GRPOF), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announced today it has entered into an five (5) year exclusive Supply and Distribution agreement with Engen Medical Corporation. (“Engen”) for the Canadian distribution of its Munchies B Gone gum. In exchange for a payment of $28,000 on signing the agreement and a minimum purchase commitment of $1,580,000 over five years, Agro-Tek will have exclusive sales and distribution rights in Canada. Engen will be responsible for all manufacturing and regulatory aspects.

    Continue Reading
  • Tetra Bio-Pharma Inc. Receives Notice of Authorization from Health Canada for the Conduct of its Clinical Trial with its PPTGR Topical Product

    1 February 2017
    0 Views

    Ottawa, Ontario – (Marketwired – February 1, 2017) – PhytoPain Pharma Inc. (“PPP”), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP),  a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that it has received a Notice of Authorization from the Therapeutic Products Directorate, Health Canada, for its planned clinical trial for PhytoPain Topical Gel Relief (“PPTGR”), being developed as a locally administered therapeutic for the treatment of Chemotherapy-Induced Neuropathic Pain (“CIPN”).

    Continue Reading
  • Tetra Bio-Pharma Inc. Completes Pre-IND Meeting with Food and Drug Administration on PPP001

    30 January 2017
    0 Views

    Ottawa, Ontario – (Marketwired – January 30, 2017) – PhytoPain Pharma Inc. (“PPP”), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP) (OTCPINK:GRPOF), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that it has completed its pre-IND meeting with the USA Food and Drug Administration (“FDA”) for its PPP001 dried cannabis drug product. The meeting was held in January 2017 with the Division of Anesthesia, Analgesia, and Addiction Products (“DAAAP”), Center for Drug Evaluation and Research (“CDER”).

    Continue Reading
  • Montreal Doctors Spearhead Cannabis Clinical Trial

    23 January 2017
    0 Views

    Gilles Richard doesn’t harbour any illusions about his disease.

    It has latched itself to his lungs, his bones and he fears it will eventually seep its way into his brain. Over time, he says, the sickness will prevail.

    “I like to say I just want five good years,” says Richard, a retired physicist. “But it could be three, it could be two. … I won’t take anything for granted.”

    Faced with this grim fate, Richard seems unfazed as he sits in the waiting room of the Santé Cannabis medical clinic on Amherst St. in Montreal’s Centre-Sud borough. The 60-year-old wears a suit and tie, he smiles at passersby and offers to chat about topics ranging from molecular biology to the latest episode of The Walking Dead.

    Continue Reading
  • Tetra BioPharma Announces it Has Entered into a Clinical Research Partnership with Santé Cannabis, Québec’s Leading Medical Cannabis Institution

    23 January 2017
    0 Views

    Ottawa, Ontario – (Marketwired – January 23, 2017) – PhytoPain Pharma Inc. (“PPP”), a subsidiary of Tetra Bio-Pharma Inc. (“TetraBio” or the “Company” or “TBP”) (CSE:TBP) is pleased to announce that it has entered into a clinical research partnership with Santé Cannabis. Under the partnership, Santé Cannabis will be working with PPP to develop the late phase clinical trial protocols that will be used to obtain substantial evidence of the safety and efficacy of PPP001 required for a new prescription drug approval from Health Canada and the USA Food and Drug Administration (“FDA”). These ground-breaking trials seek to receive the first approval for a Canadian-manufactured cannabis-based prescription medication.

    Continue Reading
  • Exclusive Interview with Tetra Bio-Pharma CSO Discussing Task Force Recommendations, DEA — CFN Media

    17 January 2017
    0 Views

    SEATTLE, WA–(Marketwired – Jan 17, 2017) – CFN Media Group (“CannabisFN”), the leading creative agency and digital media network dedicated to legal cannabis, announces publication of an exclusive interview and story covering the effect recent Canadian Cannabis Task Force recommendations and DEA actions could have on Tetra Bio-Pharma Inc. (OTC PINK: GRPOF) (CSE: TBP) as the company continues development of smokable marijuana as treatment for a variety of conditions.

    Continue Reading
  • Tetra Bio-Pharma Inc. annonce une nouvelle nomination à son conseil consultatif scientifique et clinique

    11 January 2017
    0 Views

    Ottawa (Ontario) – (Marketwired – le 11 janvier 2017) – PhytoPain Pharma Inc. (« PhytoPain Pharma » ou « PPP »), une filiale de Tetra Bio-Pharma Inc. (« Tetra » ou la « Société ») (CSE : TBP), a le plaisir d’annoncer la nomination du Dr Gilles Chamberland, M. D., FRCPC, à son conseil consultatif scientifique et clinique. Le conseil est formé d’experts en recherche clinique, en gestion de la douleur et en conception de médicaments contre le cancer et les affections neurologiques. La nomination du Dr Gilles Chamberland, M. D., au conseil consultatif de PPP conférera à cette dernière l’orientation critique nécessaire à son programme de développement clinique en ce qui concerne l’innocuité des médicaments à base de cannabis et les risques éventuels pour la santé mentale qui sont associés à la consommation de marijuana.

    Continue Reading